List of insiders holdings for Xenon Pharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| MX Associates LLP 10% Owner | 2015-01-07 12:57:30 | 1,474,660 0 | 1,474,660 | Form 4 |
| BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BIOTECHNOLOGY VALUE FUND II LP Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF INC LAMPERT MARK N 10% Owner | 2023-02-13 20:20:16 | 1,271,243 0 | 1,271,243 | Form 13G |
| STEIN EVAN A. Director | 2017-02-13 09:17:32 | 443,916 0 | 443,916 | Form 13G |
| MORTIMER IAN PRESIDENT & CEO | 2024-03-12 18:33:15 | 250,000 0 | 250,000 | Form 4 |
| HOLLER FRANK A Director | 2021-06-01 16:07:31 | 143,653 1,184 | 144,837 | Form 4 |
| Von Seggern Christopher Chief Commercial Officer | 2024-03-12 18:42:52 | 100,000 0 | 100,000 | Form 4 |
| KENNEY CHRISTOPHER JOHN Chief Medical Officer | 2024-03-12 18:38:34 | 100,000 0 | 100,000 | Form 4 |
| DiFabio Andrea Chief Legal Officer | 2024-03-12 18:34:36 | 100,000 0 | 100,000 | Form 4 |
| TARNOW MICHAEL M Director | 2021-05-20 16:18:44 | 77,942 0 | 77,942 | Form 4 |
| AZAB MOHAMMAD Director | 2023-12-20 17:04:23 | 74,225 0 | 74,225 | Form 4 |
| EMPFIELD JAMES R. EVP, Drug Discovery | 2024-03-12 18:37:25 | 65,000 0 | 65,000 | Form 4 |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-12 18:35:59 | 65,000 0 | 65,000 | Form 4 |
| AYCARDI-FONSECA ERNESTO CMO | 2020-03-13 17:06:38 | 65,000 0 | 65,000 | Form 4 |
| CORRAINI KAREN G. Gen. Counsel & Corp. Secretary | 2015-03-19 20:52:27 | 35,000 0 | 35,000 | Form 4 |
| PATOU GARY Director | 2024-11-22 19:48:02 | 23,573 4,902 | 28,475 | Form 4 |
| PIMSTONE SIMON N. Director | 2023-06-02 17:21:14 | 18,475 0 | 18,475 | Form 4 |
| Svoronos Dawn Director | 2024-06-05 17:41:36 | 15,542 0 | 15,542 | Form 4 |
| Cannon Gillian Director | 2024-06-05 17:41:52 | 15,542 0 | 15,542 | Form 4 |
| GANNON STEVEN Director | 2024-06-05 17:42:11 | 15,542 0 | 15,542 | Form 4 |
| GAROFALO ELIZABETH A. Director | 2024-06-05 17:42:24 | 15,542 0 | 15,542 | Form 4 |
| Gover Justin D. Director | 2024-06-05 17:42:40 | 15,542 0 | 15,542 | Form 4 |
| Machado Patrick Director | 2024-06-05 17:42:53 | 15,542 0 | 15,542 | Form 4 |
| SCHELLER RICHARD H Director | 2019-09-18 19:39:09 | 15,000 0 | 15,000 | Form 4 |
| GOLDBERG Y. PAUL SVP, Clinical Development | 2017-10-24 18:45:32 | 11,000 0 | 11,000 | Form 4 |
| Hayden Michael R Director | 2021-06-03 21:07:48 | 10,000 0 | 10,000 | Form 4 |
| Desjardins Clarissa Director | 2020-06-02 16:58:08 | 10,000 0 | 10,000 | Form 4 |
| COHEN CHARLES J. VP, Biology | 2018-12-13 13:56:50 | 6,550 0 | 6,550 | Form 4 |
| AULIN SHERRY Chief Financial Officer | 2024-12-19 18:57:42 | 6,000 0 | 6,000 | Form 4 |
| Bridger Gary EVP, Research & Development | 2014-11-25 21:20:38 | 5,144 0 | 5,144 | Form 4 |
| Evans Johnston L Director | 2015-05-06 15:46:21 | 3,086 0 | 3,086 | Form 4 |
| WINQUIST RAYMOND Head, Translational Research | 2017-08-21 16:48:27 | 1000 0 | 1000 | Form 4 |